Rare cancer

INVICTUS trial: positive results for patients with GIST

Ripretinib as fourth-line therapy showed to improve progression-free survival in patients with advanced gastrointestinal stromal tumours (GIST) in the phase III INVICTUS trial presented today. According to Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland,…

Watch Here